Xiangsheng Xiao

Dr. Xiangsheng Xiao


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Theranostics
Verified
Journal Article
Open access
SSSilei Sui
Silei Sui
XAXin An
Xin An
CXCaiming Xu
Caiming Xu
ZLZongjuan Li
Zongjuan Li
YHYijun Hua
Yijun Hua
WDWuguo Deng
Wuguo Deng
Background: Immune cells have essential auxiliary functions and influence clinical outcomes in cancer, with high immune infiltration being associated with improved clinical outcomes and better response to treatment in breast cancer (BC). However, studies to date have not fully considered the tumor-infiltrating immune cell (TIIC) landscape in tumors. This study investigated potential biomarkers based on TIICs to improve prognosis and treatment effect in BC.

24 January 2022 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
ZWZehao Wang
Zehao Wang
LYLu Yang
Lu Yang
PWPeng Wu
Peng Wu
XLXing Li
Xing Li
Yuhui TangYuhui Tang
Yuhui Tang
HTHailin Tang
Hailin Tang
Background: Metastasis causes the majority of cancer-related deaths worldwide. Increasing studies have revealed that circRNAs are associated with the carcinogenesis and metastasis of many cancers. Nevertheless, the biological mechanisms of circRNAs in breast cancer (BC) liver metastasis remain extremely ambiguous. Methods: In this study, we identified circROBO1 from three pairs of primary BC and metastatic liver sites by RNA sequencing. FISH assays and RT-qPCR were conducted to validate the existence and expression of circROBO1. The oncogenic role of circROBO1 was demonstrated both in vitro and in vivo. Western blot, ChIP, RIP, RNA pull-down, and dual-luciferase reporter assays were used to confirm the interaction of the feedback loop among circROBO1, miR-217-5p, KLF5, and FUS. Meanwhile, the regulation of selective autophagy was investigated by immunofluorescence, CoIP, and western blot. Results: In this study, upregulated expression of circROBO1 was found in BC-derived liver metastases and was correlated with poor prognosis. Knockdown of circROBO1 strikingly inhibited the proliferation, migration, and invasion of BC cells, whereas overexpression of circROBO1 showed the opposite effects. Moreover, overexpression of circROBO1 promoted tumor growth and liver metastasis in vivo. Further research revealed that circROBO1 could upregulate KLF5 by sponging miR-217-5p, allowing KLF5 to activate the transcription of FUS, which would promote the back splicing of circROBO1. Therefore, a positive feedback loop comprising circROBO1/KLF5/FUS was formed. More importantly, we found that circROBO1 inhibited selective autophagy of afadin by upregulating KLF5. Conclusions: Our results demonstrated that circROBO1 facilitates the carcinogenesis and liver metastasis of BC through the circROBO1/KLF5/FUS feedback loop, which inhibits the selective autophagy of afadin by suppressing the transcription of BECN1. Therefore, circROBO1 could be used not only as a potential prognostic marker but also as a therapeutic target in BC.

20 October 2021 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
MBMeiheban Bazhabayi
Meiheban Bazhabayi
XQXingsheng Qiu
Xingsheng Qiu
XLXing Li
Xing Li
AYAnli Yang
Anli Yang
WWWei Wen
Wei Wen
PLPeng Liu
Peng Liu
CircRNAs (circular RNA) are reported to regulate onset and progress multiple cancers. Nonetheless, the function along with the underlying mechanisms of circRNAs in HER‐2‐positive breast cancer (BC) remains unclear. CircRNA microarrays were performed to elucidate expression profiles of HER‐2‐positive BC cells. circRNA levels were quantified using qRT‐PCR assay. Various in vitro along with in vivo assays were employed to further explore the effects of circGFRA1 in the progress of HER‐2‐positive BC and interactions of circGFRA1, miR‐1228 and AIFM2 in Her‐2‐positive BC. CircGFRA1 was remarkably upregulated in HER‐2‐positive BC. Knockdown of circGFRA1 could attenuate HER‐2‐positive BC progression by inhibiting the proliferation, infiltration and migratory ability of HER‐2‐positive BC cells. Through ceRNA mechanism, circGFRA1 could bind to miR‐1228 and alleviate inhibitory activity of miR‐1228 on targeted gene AIFM2. In summary, circGFRA1‐miR‐1228‐AIFM2 axis regulates HER‐2‐positive BC. CircGFRA1 is a novel promising treatment option for HER‐2‐positive BC.

1 January 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
JWJiali Wu
Jiali Wu
ZSZeyu Shuang
Zeyu Shuang
JZJianfu Zhao
Jianfu Zhao
HTHailin Tang
Hailin Tang
PLPeng Liu
Peng Liu
XXXiangsheng Xiao
Xiangsheng Xiao

16 November 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
KZKaiming Zhang
Kaiming Zhang
PLPeng Liu
Peng Liu
HTHailin Tang
Hailin Tang
XXXiaoming Xie
Xiaoming Xie
YKYanan Kong
Yanan Kong
XXXiangsheng Xiao
Xiangsheng Xiao
Long non-coding RNA (LncRNA) actin filament-associated protein1-antisense RNA 1 (AFAP1-AS1) is overexpressed in various types of cancers and plays an important role in tumor progression and prognosis. This study investigates the role of AFAP1-AS1 in tumor progression in triple-negative breast cancer (TNBC). We found that AFAP1-AS1 was overexpressed in TNBC tissues and cells. Overexpression of LncRNA AFAP1-AS1 was associated with poor prognosis in TNBC patients. Moreover, we demonstrated that upregulation of AFAP1-AS1 promoted cell proliferation and invasion, and inhibited cell apoptosis in vitro, while overexpression of AFAP1-AS1 promoted tumor growth in vivo. Our results also revealed that upregulation of AFAP1-AS1 activated Wnt/β-catenin pathway to promote tumorigenesis and cell invasion by increasing the expression of C-myc and epithelial-mesenchymal transition-related molecules in TNBC. Collectively, AFAP1-AS1 can be an independent prognostic marker and an effective therapeutic target of triple- negative breast cancer.

26 April 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
LFLingyi Fu
Lingyi Fu
KSKe Shi
Ke Shi
JWJingshu Wang
Jingshu Wang
WCWangbing Chen
Wangbing Chen
DSDingbo Shi
Dingbo Shi
WDWuguo Deng
Wuguo Deng
TFAP2B is a member of the AP2 transcription factor family, which orchestrates a variety of cell processes. However, the roles of TFAP2B in regulating carcinogenesis remain largely unknown. Here, we investigated the regulatory effects of TFAP2B on lung adenocarcinomas growth and identified the underlying mechanisms of actions in non-small cell lung cancer (NSCLC) cells. We first examined the expression of TFAP2B in lung cancer cell lines and tumor tissues. We also analyzed the prognostic predicting value of TFAP2B in lung adenocarcinomas. Then we investigated the molecular mechanisms by which TFAP2B knockdown or overexpression regulated lung cancer cell growth, angiogenesis and apoptosis, and further confirmed the role of TFAP2B in tumor growth in a lung cancer xenograft mouse model. TFAP2B was highly expressed in NSCLC cell lines and tumor tissues. Strong TFAP2B expression showed a positive correlation with the poor prognoses of patients with lung adenocarcinomas (P < 0.001). TFAP2B knockdown by siRNA significantly inhibited cell growth and induced apoptosis in NSCLC cells in vitro and in a lung cancer subcutaneous xenograft model, whereas TFAP2B overexpression promoted cell growth. The observed regulation of cell growth was accompanied by the TFAP2B-mediated modulation of the ERK/p38, caspase/cytochrome-c and VEGF/PEDF-dependent signaling pathways in NSCLC cells. These results indicate that TFAP2B plays a critical role in regulating lung adenocarcinomas growth and could serve as a promising therapeutic target for lung cancer treatment.